
  
    
      
        Background_NNP
        Three_CD recent_JJ reports_NNS ,_, from_IN the_DT Study_NNP of_IN Osteoporotic_NNP
        Fractures_NNP [_NN 1_CD ]_NN ,_, Framingham_NNP [_NN 2_CD ]_NN ,_, and_CC the_DT Fracture_NNP
        Intervention_NN Trial_NNP [_NN 3_CD ]_NN demonstrated_VBD a_DT positive_JJ
        association_NN between_IN bone_NN mineral_NN density_NN measurements_NNS (_( BMD_NNP )_)
        in_IN women_NNS and_CC subsequent_JJ onset_NN of_IN breast_NN cancer_NN ._. All_DT of_IN
        these_DT reports_NNS were_VBD regarded_VBN as_IN significant_JJ because_IN estrogen_NN
        has_VBZ been_VBN thought_VBN to_TO increase_VB breast_NN cancer_NN risk_NN [_NN 4_CD ]_NN and_CC
        BMD_NNP may_MD be_VB a_DT more_RBR accurate_JJ measure_NN of_IN long_JJ term_NN estrogen_NN
        exposure_NN than_IN recall_NN of_IN hormone_NN supplementation_NN ,_,
        measurements_NNS of_IN endogenous_JJ estrogen_NN ,_, parity_NN ,_, or_CC obesity_NN [_NN 5_CD
        6_CD ]_NN ._.
        In_IN the_DT light_NN of_IN strong_JJ associations_NNS previously_RB noted_VBD
        between_IN estrogens_NNS and_CC corpus_NN uteri_NN cancer_NN ,_, BMD_NNP should_MD
        predict_VB the_DT occurrence_NN of_IN endometrial_NN cancer_NN [_NN 4_CD ]_NN ,_, though_IN
        this_DT has_VBZ not_RB yet_RB been_VBN directly_RB assessed_VBN ._. BMD_NNP also_RB reflects_VBZ
        exposure_NN to_TO calcium_NN and_CC to_TO physical_JJ activity_NN as_RB well_RB as_IN
        foods_NNS affecting_VBG calcium_NN absorption_NN and_CC deposition_NN [_NN 7_CD 8_CD 9_CD ]_NN
        ._. All_DT of_IN these_DT factors_NNS ,_, including_VBG estrogen_NN ,_, are_VBP thought_VBN to_TO
        diminish_VB the_DT risk_NN of_IN colorectal_NN cancer_NN [_NN 10_CD 11_CD ]_NN ._. On_IN the_DT
        other_JJ hand_NN increased_VBD calcium_NN intake_NN has_VBZ been_VBN associated_VBN
        with_IN increased_VBN risk_NN of_IN prostate_NN cancer_NN [_NN 12_CD 13_CD ]_NN ._. Because_IN
        of_IN the_DT intimate_JJ association_NN of_IN BMD_NNP with_IN to_TO all_DT of_IN these_DT
        exposure_NN variables_NNS ,_, BMD_NNP needs_VBZ to_TO be_VB examined_VBN in_IN relation_NN to_TO
        each_DT of_IN these_DT cancers_NNS ._. In_IN this_DT report_NN we_PRP use_VBP the_DT NHANES_NNP I_PRP
        Epidemiological_NNP Followup_NNP Study_NNP to_TO pursue_VB four_CD hypotheses_NNS
        relating_VBG BMD_NNP to_TO cancer_NN :_: that_IN BMD_NNP will_MD correlate_VBP directly_RB
        with_IN subsequent_JJ breast_NN ,_, uterus_NN ,_, and_CC prostate_NN cancer_NN
        incidence_NN ,_, and_CC that_IN BMD_NNP will_MD correlate_VBP inversely_RB with_IN
        subsequent_JJ colorectal_NN cancer_NN incidence_NN ._.
      
      
        Methods_NNP
        The_DT First_CD National_NNP Health_NNP and_CC Nutrition_NNP Examination_NNP
        Survey_NNP (_( NHANES_NNP I_PRP )_) collected_VBN data_NNS from_IN a_DT national_JJ
        probability_NN sample_NN of_IN the_DT United_NNP States_NNPS civilian_JJ
        noninstitutionalized_JJ population_NN between_IN the_DT ages_NNS of_IN one_CD and_CC
        seventy-four_JJ years_NNS [_NN 14_CD ]_NN ._. The_DT initial_JJ survey_NN took_VBD place_NN
        from_IN 1971_CD through_IN 1974_CD ._. In_IN addition_NN to_TO the_DT emphasis_NN on_IN
        nutrition_NN in_IN NHANES_NNP I_PRP ,_, a_DT subset_NN sample_NN of_IN persons_NNS age_VBP 25_CD -_: 74_CD
        received_VBD a_DT more_RBR detailed_JJ health_NN examination_NN through_IN October_NNP
        1975_CD ._. This_DT additional_JJ exam_NN included_VBD a_DT hand_NN /_NN wrist_NN x-ray_JJ ._.
        This_DT was_VBD successfully_RB completed_VBN in_IN 6_CD ,_, 413_CD subjects_NNS ._. Each_DT
        x-ray_JJ was_VBD a_DT posterior_NN /_NN anterior_NN view_NN of_IN the_DT left_NN hand_NN and_CC
        wrist_NN taken_VBN by_IN direct_JJ exposure_NN using_VBG 10_CD Ã—_NN 12_CD Eastman_NNP
        Industrial_NNP Type_NNP AA_NN "_'' Ready_NNP Pak_NNP "_'' film_NN ._. The_DT prescribed_VBN
        radiography_NN technique_NN called_VBN for_IN a_DT focus_NN to_TO film_NN distance_NN
        of_IN 36_CD inches_NNS with_IN the_DT focal_JJ spot_NN centered_VBN on_IN the_DT midpoint_NN
        of_IN the_DT third_JJ metacarpal_NN ._. These_DT hand_NN /_NN wrist_NN x-rays_JJ were_VBD
        originally_RB evaluated_VBN for_IN BMD_NNP by_IN photo_NN densitometry_NN
        measurements_NNS of_IN the_DT phalanx_NN V-_NNP 2_CD and_CC the_DT radius_JJ ._. BMD_NNP was_VBD
        determined_VBN from_IN the_DT radiography_NN using_VBG a_DT reference_NN wedge_NN ._.
        The_DT hand_NN /_NN wrist_NN x-rays_JJ have_VBP since_IN been_VBN reread_NN for_IN bone_NN
        density_NN using_VBG a_DT technique_NN called_VBD Osteo_NNP Gram_NNP Radiographic_NNP
        Absorptiometry_NNP (_( RA_NNP )_) by_IN Compu-_NNP Med_NNP Incorporated_NNP ._. BMD_NNP could_MD
        not_RB be_VB calculated_VBN using_VBG this_DT method_NN for_IN 153_CD of_IN the_DT 6_CD ,_, 413_CD
        subjects_NNS with_IN hand_NN x-rays_JJ due_NN to_TO improper_JJ exposure_NN ,_, poor_JJ
        picture_NN quality_NN ,_, damaged_VBN or_CC missing_VBG film_NN ._. Records_NNPS for_IN the_DT
        6_CD ,_, 260_CD cases_NNS that_WDT have_VBP been_VBN reread_NN are_VBP contained_VBN in_IN the_DT
        Public_NNP Use_NNP File_NNP (_( Radiography_NNP Absorptiometry_NNP Bone_NNP Density_NNP )_) ._.
        Additional_JJ data_NNS on_IN RA_NNP can_MD be_VB found_VBN in_IN an_DT introduction_NN to_TO
        that_DT public_JJ use_NN file_NN ._. RA_NNP has_VBZ been_VBN found_VBN to_TO have_VB an_DT
        excellent_JJ precision_NN (_( CV_NNP of_IN 0_CD ._. 6_CD %_NN )_) and_CC accuracy_NN and_CC to_TO
        correlate_VBP well_RB with_IN other_JJ accepted_VBD methods_NNS of_IN bone_NN
        densitometry_NN ._.
        Data_NNS on_IN disease_NN incidence_NN were_VBD obtained_VBN on_IN the_DT
        individuals_NNS from_IN the_DT NHANES_NNP I_PRP Epidemiologic_NNP Followup_NNP
        Studies_NNPS (_( NHEFS_NNP )_) ,_, which_WDT was_VBD conducted_VBN in_IN four_CD waves_NNS of_IN data_NNS
        collection_NN through_IN 1993_CD ._. Data_NNP collected_VBD included_VBN in_IN depth_NN
        interviews_NNS with_IN subjects_NNS or_CC their_PRP$ proxies_NNS ,_, hospital_NN
        records_NNS ,_, including_VBG pathology_NN reports_NNS ,_, and_CC collection_NN of_IN
        death_NN certificates_NNS for_IN deceased_JJ subjects_NNS ._. Tracing_NNP is_VBZ
        complete_JJ for_IN 90_CD %_NN of_IN the_DT cohort_NN through_IN 1993_CD ._.
        Those_DT with_IN at_IN least_JJS one_CD follow-up_JJ record_NN in_IN NHEFS_NNP were_VBD
        included_VBN in_IN the_DT analysis_NN ,_, resulting_VBG in_IN a_DT final_JJ sample_NN size_NN
        of_IN 6_CD ,_, 046_CD ._. Disease_NN outcomes_NNS were_VBD obtained_VBN using_VBG ICD-_NNP 9_CD codes_NNS
        (_( International_NNP Classification_NNP of_IN Diseases_NNP ,_, 9_CD th_NN Revision_NNP )_)
        from_IN death_NN certificates_NNS and_CC hospital_NN record_NN diagnostic_JJ
        codes_NNS in_IN NHEFS_NNP mortality_NN and_CC health_NN care_NN facility_NN stay_NN data_NNS
        bases_NNS ,_, respectively_RB ._. They_PRP were_VBD :_: uterine_NN cancer_NN (_( 179_CD ,_, 182_CD ._. 0_CD ,_,
        182_CD ._. 1_LS ,_, 182_CD ._. 8_CD )_) ,_, colorectal_NN cancer_NN (_( 153_CD ._. 0_CD -_: 154_CD ._. 3_LS ,_, 154_CD ._. 8_CD )_) ,_,
        breast_NN cancer_NN (_( 174_CD ._. 0_CD -_: 174_CD ._. 9_CD )_) ,_, prostate_NN cancer_NN (_( 185_CD )_) ,_, hip_NN
        fractures_NNS (_( 820_CD ._. 0_CD -_: 820_CD ._. 3_LS ,_, 820_CD ._. 8_CD ,_, 820_CD ._. 9_CD )_) ,_, and_CC osteoporosis_NNS
        (_( 733_CD ._. 00_CD -_: 733_CD ._. 03_CD ,_, 733_CD ._. 09_CD )_) ._.
        Person-years_NNP of_IN follow-up_JJ were_VBD computed_JJ for_IN each_DT cohort_NN
        as_IN the_DT amount_NN of_IN time_NN since_IN the_DT NHANES_NNP I_PRP examination_NN to_TO the_DT
        date_NN of_IN the_DT first_JJ of_IN the_DT following_JJ events_NNS :_: date_NN of_IN ICD-_NNP 9_CD
        disease_NN code_NN of_IN interest_NN from_IN the_DT health_NN care_NN facility_NN stay_NN
        files_NNS ,_, date_NN of_IN death_NN from_IN the_DT NHEFS_NNP mortality_NN file_NN ,_, or_CC the_DT
        last_JJ day_NN of_IN contact_NN from_IN the_DT 1992_CD NHEFS_NNP vital_JJ status_NN file_NN ._.
        Thus_RB ,_, subjects_NNS were_VBD right-censored_JJ at_IN either_DT death_NN or_CC last_JJ
        date_NN of_IN follow-up_JJ ._. For_IN persons_NNS with_IN more_JJR than_IN one_CD hospital_NN
        admission_NN listing_VBG a_DT particular_JJ disease_NN outcome_NN of_IN interest_NN ,_,
        the_DT date_NN of_IN the_DT earliest_JJS admission_NN for_IN that_DT disease_NN was_VBD
        used_VBN ._. Person-years_NNP of_IN follow-up_JJ were_VBD calculated_VBN separately_RB
        for_IN each_DT disease_NN outcome_NN ._. Cohorts_NNP who_WP reported_VBD at_IN baseline_NN
        a_DT history_NN of_IN hip_NN fracture_NN were_VBD excluded_VBN from_IN the_DT hip_NN
        fracture_NN analysis_NN (_( 30_CD women_NNS and_CC 27_CD men_NNS )_) for_IN a_DT total_JJ sample_NN
        size_NN of_IN 5989_CD ,_, and_CC those_DT who_WP reported_VBD a_DT prior_RB malignant_JJ
        tumor_NN or_CC growth_NN were_VBD excluded_VBN from_IN the_DT cancer_NN analyses_NNS (_( 120_CD
        women_NNS and_CC 49_CD men_NNS )_) for_IN total_JJ sample_NN sizes_NNS of_IN 5877_CD for_IN the_DT
        colorectal_NN cancer_NN analysis_NN ,_, 3108_CD women_NNS for_IN the_DT breast_NN and_CC
        uterine_NN cancer_NN analyses_NNS ,_, and_CC 2769_CD men_NNS for_IN the_DT prostate_NN
        cancer_NN analysis_NN ._.
        Cohorts_NNP were_VBD divided_VBN into_IN 4_CD groups_NNS according_VBG to_TO their_PRP$ RA_NNP
        BMD_NNP :_: <_NN 95_CD ,_, 95_CD -_: 105_CD ,_, 105_CD -_: 115_CD ,_, >_NN 115_CD (_( mass_NN /_NN volume_NN units_NNS
        established_VBN by_IN Compu-_NNP Med_NNP )_) ._. Chi_NNP square_JJ tests_NNS for_IN trend_NN and_CC
        linear_JJ regression_NN analysis_NN using_VBG a_DT single_JJ variable_NN for_IN
        RA-BMD_NNP group_NN were_VBD used_VBN to_TO evaluate_VB the_DT relationship_NN of_IN BMD_NNP
        to_TO BMI_NNP ,_, gender_NN ,_, age_NN and_CC ethnicity_NN ,_, as_IN appropriate_JJ ._. For_IN each_DT
        diagnosis_NN of_IN interest_NN ,_, incidence_NN rates_NNS were_VBD calculated_VBN for_IN
        each_DT BMD_NNP group_NN by_IN dividing_VBG the_DT number_NN of_IN cases_NNS of_IN disease_NN
        by_IN the_DT number_NN of_IN person-years_JJ of_IN follow-up_JJ ._. Cox_NNP
        proportional-hazards_JJ models_NNS were_VBD fitted_JJ for_IN disease_NN
        outcomes_NNS with_IN BMD_NNP groups_NNS using_VBG the_DT PHREG_NNP procedure_NN from_IN the_DT
        SAS_NNP System_NNP for_IN Windows_NNP Version_NNP 8_CD ._. 01_CD ._. Covariates_NNP in_IN the_DT
        analysis_NN were_VBD age_NN at_IN NHANES_NNP I_PRP examination_NN (_( <_NN 35_CD ,_, 35_CD -_: 50_CD ,_,
        50_CD -_: 60_CD ,_, and_CC >_NN 60_CD years_NNS )_) ,_, body_NN mass_NN index_NN (_( BMI_NNP ;_: weight_NN in_IN
        kg_NN /_NN height_NN in_IN m_NN 2_LS )_) at_IN NHANES_NNP I_PRP examination_NN (_( <_NN 22_CD ,_, 22_CD -_: 25_CD ,_,
        25_CD -_: 28_CD ,_, >_NN 28_CD )_) ,_, and_CC race_NN (_( Caucasian_NNP versus_CC other_JJ )_) ._. Analyses_NNS
        of_IN colorectal_NN cancer_NN ,_, hip_NN fractures_NNS and_CC osteoporosis_NNS
        outcomes_NNS were_VBD adjusted_VBN for_IN gender_NN ._. Similar_JJ models_NNS ,_,
        replacing_VBG the_DT 3_CD indicator_NN variables_NNS for_IN RA_NNP BMD_NNP with_IN a_DT
        single_JJ variable_NN for_IN RA_NNP BMD_NNP group_NN ,_, were_VBD tested_VBN to_TO determine_VB
        the_DT significance_NN of_IN the_DT trend_NN in_IN risk_NN of_IN disease_NN ._. For_IN the_DT
        analysis_NN including_VBG only_RB women_NNS older_JJR than_IN 55_CD years_NNS ,_, the_DT
        cohort_NN was_VBD divided_VBN into_IN 4_CD groups_NNS according_VBG to_TO BMD_NNP quartile_NN ._.
        The_DT association_NN of_IN BMD_NNP quartile_NN with_IN breast_NN cancer_NN in_IN women_NNS
        older_JJR than_IN 55_CD was_VBD tested_VBN using_VBG Cox_NNP proportional_JJ hazards_NNS
        models_NNS as_IN described_VBN above_IN ._. Covariates_NNP included_VBN in_IN the_DT model_NN
        were_VBD indicator_NN variables_NNS for_IN quartile_NN of_IN age_NN ,_, quartile_NN of_IN
        BMI_NNP ,_, and_CC race_NN (_( Caucasian_NNP versus_CC other_JJ )_) ._. Since_IN we_PRP would_MD
        expect_VB that_DT age_NN would_MD be_VB exponentially_RB related_VBN to_TO cancer_NN ,_,
        and_CC for_IN breast_NN and_CC uterine_NN cancer_NN the_DT slope_NN of_IN the_DT
        exponential_NN line_NN would_MD change_VB after_IN menopause_NN ,_, the_DT use_NN of_IN
        age_NN categories_NNS did_VBD not_RB constrain_VB age_NN to_TO be_VB linearly_RB related_VBN
        to_TO the_DT outcome_NN ._.
      
      
        Results_NNS
        The_DT BMD_NNP sample_NN of_IN NHANES_NNP I_PRP included_VBD 6_CD ,_, 046_CD individuals_NNS
        who_WP had_VBD bone_NN density_NN read_VBN by_IN RA_NNP and_CC follow-up_JJ data_NNS in_IN
        NHEFS_NNP ._. This_DT group_NN included_VBD 5_CD ,_, 252_CD Caucasians_NNP ,_, 742_CD African_NNP
        Americans_NNPS ,_, and_CC 52_CD individuals_NNS of_IN Hispanic_JJ origin_NN ._. There_EX
        were_VBD 2_CD ,_, 818_CD men_NNS and_CC 3_CD ,_, 228_CD women_NNS ._. The_DT median_JJ age_NN at_IN the_DT
        time_NN of_IN bone_NN density_NN reading_NN was_VBD slightly_RB less_JJR than_IN 50_CD
        years_NNS ._. Table_NNP 1_CD describes_VBZ the_DT relationship_NN of_IN gender_NN and_CC race_NN
        to_TO age_NN ,_, body_NN mass_NN index_NN ,_, and_CC BMD_NNP within_IN the_DT cohort_NN ._.
        By_IN 1993_CD ,_, a_DT total_NN of_IN 103_CD cases_NNS of_IN osteoporosis_NNS ,_, 110_CD cases_NNS
        of_IN reported_JJ hip_NN fracture_NN ,_, 115_CD cases_NNS of_IN colorectal_NN cancer_NN ,_,
        100_CD cases_NNS of_IN breast_NN cancer_NN ,_, 94_CD cases_NNS of_IN prostate_NN cancer_NN and_CC
        26_CD cases_NNS of_IN uterine_NN cancer_NN had_VBD been_VBN reported_VBN within_IN this_DT
        subset_NN of_IN the_DT NHANES_NNP I_PRP cohort_NN ._. Significant_JJ inverse_NN
        associations_NNS were_VBD seen_VBN with_IN both_DT osteoporosis_NNS and_CC hip_NN
        fracture_NN (_( Table_NNP 2_LS )_) after_IN adjustment_NN for_IN age_NN ,_, BMI_NNP ,_, race_NN ,_, and_CC
        gender_NN ._.
        Table_NNP 3_CD describes_VBZ the_DT relationship_NN of_IN BMD_NNP to_TO uterine_NN
        cancer_NN risk_NN ._. After_IN age_NN ,_, race_NN and_CC BMI_NNP adjustment_NN there_EX was_VBD a_DT
        significant_JJ (_( p_NN =_SYM 0_CD ._. 005_CD )_) trend_NN to_TO increasing_VBG risk_NN with_IN
        increasing_VBG BMD_NNP ._.
        A_DT trend_NN was_VBD not_RB seen_VBN between_IN BMD_NNP and_CC the_DT subsequent_JJ
        incidence_NN of_IN breast_NN cancer_NN in_IN the_DT overall_JJ cohort_NN (_( Table_NNP 4_CD :_:
        p_NN =_SYM 0_CD ._. 74_CD )_) ._. However_RB ,_, in_IN women_NNS who_WP were_VBD over_IN the_DT age_NN of_IN 55_CD (_( n_NN
        =_SYM 1091_CD )_) ,_, that_WDT is_VBZ ,_, probably_RB after_IN the_DT age_NN of_IN menopause_NN at_IN
        the_DT time_NN that_IN their_PRP$ BMD_NNP was_VBD measured_VBN ,_, a_DT positive_JJ
        association_NN of_IN BMD_NNP and_CC breast_NN cancer_NN was_VBD suggested_VBN (_( p_NN =_SYM
        0_CD ._. 04_CD for_IN trend_NN in_IN a_DT quartile_NN comparison_NN )_) ._. A_DT total_NN of_IN 43_CD
        breast_NN cancers_NNS developed_VBN in_IN this_DT latter_NN ,_, older_JJR group_NN ._.
        There_EX was_VBD an_DT inverse_NN association_NN of_IN BMD_NNP with_IN colorectal_NN
        cancer_NN after_IN adjustment_NN for_IN age_NN ,_, race_NN ,_, BMI_NNP ,_, and_CC gender_NN that_WDT
        was_VBD statistically_RB significance_NN (_( p_NN =_SYM 0_CD ._. 03_CD :_: Table_NNP 5_LS )_) ._.
        Prostate_NNP cancer_NN risk_NN was_VBD not_RB significantly_RB associated_VBN
        with_IN increasing_VBG levels_NNS of_IN BMD_NNP (_( p_NN =_SYM 0_CD ._. 37_CD )_) ,_, although_IN there_EX
        were_VBD diminished_VBN risks_NNS in_IN upper_JJ quartiles_NNS of_IN BMD_NNP ,_, which_WDT was_VBD
        in_IN the_DT opposite_JJ direction_NN of_IN our_PRP$ hypothesis_NNS (_( Table_NNP 6_CD )_) ._.
      
      
        Discussion_NNP
        
          Hip_NNP fracture_NN and_CC osteoporosis_NNS
          As_IN in_IN the_DT Framingham_NNP cohort_NN ,_, the_DT choice_NN of_IN bone_NN for_IN
          BMD_NNP measurement_NN in_IN NHANES_NNP I_PRP was_VBD the_DT metacarpal_NN [_NN 2_CD ]_NN ._.
          Much_JJ has_VBZ been_VBN written_VBN about_IN the_DT optimal_NN choice_NN of_IN bone_NN
          for_IN BMD_NNP measurement_NN ,_, though_IN no_DT clear_JJ preference_NN has_VBZ
          dominated_VBN this_DT literature_NN [_NN 15_CD 16_CD 17_CD ]_NN ._. Because_IN we_PRP
          assumed_VBD that_IN the_DT most_RBS direct_JJ consequences_NNS of_IN diminished_VBN
          BMD_NNP would_MD be_VB osteoporosis_NNS and_CC hip_NN fracture_NN ,_, associations_NNS
          of_IN BMD_NNP with_IN hip_NN fracture_NN and_CC the_DT development_NN of_IN
          osteoporosis_NNS were_VBD investigated_VBN in_IN order_NN to_TO establish_VB the_DT
          validity_NN of_IN this_DT BMD_NNP measurement_NN in_IN this_DT cohort_NN ._. As_IN
          anticipated_VBN ,_, in_IN the_DT NHEFS_NNP ,_, diminished_VBD BMD_NNP is_VBZ
          significantly_RB associated_VBN with_IN the_DT development_NN of_IN
          osteoporosis_NNS and_CC hip_NN fracture_NN (_( Table_NNP 2_LS )_) ._.
        
        
          Uterine_NNP cancer_NN
          This_DT is_VBZ the_DT first_JJ report_NN that_WDT examines_VBZ the_DT
          relationship_NN of_IN BMD_NNP to_TO uterine_NN cancer_NN ._. Because_IN the_DT
          association_NN of_IN estrogen_NN exposure_NN and_CC uterine_NN cancer_NN
          development_NN is_VBZ far_RB less_RBR controversial_JJ than_IN estrogen_NN and_CC
          breast_NN cancer_NN risk_NN [_NN 4_CD ]_NN ,_, the_DT veracity_NN of_IN BMD_NNP as_IN a_DT
          measure_NN of_IN estrogen_NN exposure_NN is_VBZ supported_VBN by_IN the_DT
          significant_JJ positive_JJ association_NN of_IN BMD_NNP with_IN uterine_NN
          cancer_NN incidence_NN (_( Table_NNP 3_LS )_) ._.
        
        
          Breast_NNP cancer_NN
          Although_IN no_DT association_NN between_IN BMD_NNP and_CC subsequent_JJ
          breast_NN cancer_NN incidence_NN was_VBD found_VBN for_IN all_DT women_NNS in_IN the_DT
          cohort_NN ,_, a_DT weak_JJ but_CC significant_JJ association_NN was_VBD seen_VBN in_IN
          those_DT over_IN 55_CD years_NNS of_IN age_NN at_IN the_DT time_NN of_IN BMD_NNP
          measurement_NN ,_, i_NNP ._. e_SYM ._. post_NN menopause_NN ._. The_DT total_JJ number_NN of_IN
          breast_NN cancer_NN cases_NNS is_VBZ comparable_JJ to_TO the_DT three_CD studies_NNS
          discussed_VBN below_IN ,_, as_IN is_VBZ the_DT size_NN of_IN the_DT cohort_NN ._. However_RB ,_,
          the_DT three_CD previous_JJ studies_NNS all_DT recruited_VBN peri-_NN and_CC
          post-menopausal_JJ women_NNS [_NN 1_CD 2_CD 3_CD ]_NN ,_, an_DT age_NN group_NN that_WDT
          comprised_VBN just_RB less_JJR than_IN half_PDT the_DT women_NNS in_IN the_DT NHANES_NNP I_PRP
          BMD_NNP cohort_NN ._. The_DT NHANES_NNP I_PRP female_JJ BMD_NNP cohort_NN size_NN and_CC
          number_NN of_IN breast_NN cancer_NN cases_NNS in_IN this_DT post-menopausal_JJ
          subgroup_NN are_VBP therefore_RB smaller_JJR than_IN the_DT other_JJ studies_NNS ._.
          Nevertheless_RB ,_, there_EX is_VBZ a_DT significant_JJ ,_, though_IN unstable_JJ
          trend_NN towards_IN increasing_VBG breast_NN cancer_NN risk_NN with_IN rising_VBG
          BMD_NNP in_IN those_DT women_NNS recruited_VBN to_TO NHANES_NNP I_PRP older_JJR than_IN 55_CD
          years_NNS (_( Table_NNP 4_LS )_) ._.
          The_DT relationship_NN of_IN estrogen_NN exposure_NN to_TO subsequent_JJ
          breast_NN cancer_NN risk_NN has_VBZ been_VBN the_DT subject_NN of_IN much_JJ debate_NN
          and_CC investigation_NN [_NN 4_CD ]_NN ._. The_DT debate_NN is_VBZ all_PDT the_DT more_RBR
          significant_JJ because_IN of_IN estrogen_NN 's_POS possible_JJ role_NN in_IN the_DT
          prevention_NN of_IN coronary_JJ heart_NN disease_NN mortality_NN ,_, hip_NN
          fracture_NN and_CC osteoporosis_NNS [_NN 5_CD ]_NN ._. Three_CD studies_NNS were_VBD
          greeted_VBN with_IN great_JJ enthusiasm_NN because_IN they_PRP added_VBD a_DT new_JJ
          perspective_NN to_TO the_DT debate_NN ,_, correlating_VBG BMD_NNP with_IN breast_NN
          cancer_NN risk_NN ._. In_IN so_RB doing_VBG they_PRP seemed_VBD to_TO confirm_VB that_DT
          estrogen_NN exposure_NN over_IN a_DT long_JJ period_NN of_IN time_NN increased_VBD
          the_DT risk_NN of_IN breast_NN cancer_NN [_NN 1_CD 2_CD 3_CD ]_NN ,_, (_( Table_NNP 7_CD )_) ._. In_IN the_DT
          Study_NNP of_IN Osteoporotic_NNP Fractures_NNP ,_, 6_CD ,_, 854_CD women_NNS greater_JJR
          than_IN 65_CD years_NNS old_JJ had_VBD their_PRP$ BMD_NNP measured_VBD and_CC were_VBD
          followed-up_JJ for_IN an_DT average_NN of_IN 3_CD ._. 2_CD years_NNS ._. Ninety-seven_NNP
          women_NNS developed_VBD breast_NN cancer_NN [_NN 1_CD ]_NN ._. The_DT incidence_NN rate_NN
          of_IN breast_NN cancer_NN varied_VBD from_IN 2_CD ._. 46_CD cases_NNS /_NN 1000_CD person_NN
          years_NNS in_IN the_DT lowest_JJS quartile_NN of_IN bone_NN mineral_NN density_NN to_TO
          5_CD ._. 99_CD cases_NNS /_NN 1000_CD person_NN years_NNS in_IN the_DT highest_JJS quartile_NN
          (_( relative_JJ risk_NN 1_CD ._. 50_CD :_: 95_CD %_NN confidence_NN interval_NN =_SYM 1_CD ._. 16_CD to_TO
          1_CD ._. 95_CD )_) ._.
          In_IN the_DT Framingham_NNP study_NN ,_, 1_CD ,_, 373_CD women_NNS age_VBP 47_CD to_TO 80_CD
          years_NNS had_VBD bone_NN density_NN measured_VBN from_IN 1967_CD to_TO 1970_CD ._. By_IN
          1993_CD ,_, 91_CD women_NNS developed_VBD breast_NN cancer_NN [_NN 2_CD ]_NN ._. The_DT age_NN
          adjusted_VBD rate_NN ratios_NNS for_IN breast_NN cancer_NN from_IN the_DT lowest_JJS to_TO
          the_DT highest_JJS quartile_NN of_IN BMD_NNP were_VBD 1_CD ._. 0_CD ,_, 1_CD ._. 3_CD ,_, 1_CD ._. 3_CD and_CC 1_CD ._. 5_CD
          respectively_RB ._. However_RB ,_, the_DT effect_NN was_VBD found_VBN to_TO be_VB far_RB
          greater_JJR in_IN women_NNS with_IN a_DT positive_JJ family_NN history_NN of_IN breast_NN
          cancer_NN in_IN the_DT Framingham_NNP report_NN ._. Among_IN those_DT without_IN a_DT
          family_NN history_NN of_IN breast_NN cancer_NN ,_, the_DT risk_NN was_VBD not_RB
          significantly_RB increased_VBN [_NN 18_CD ]_NN ._.
          In_IN the_DT Fracture_NNP Intervention_NN Trial_NNP ,_, 8203_CD
          postmenopausal_NN women_NNS between_IN 54_CD and_CC 80_CD years_NNS of_IN age_NN were_VBD
          enrolled_VBN in_IN a_DT therapeutic_JJ trial_NN related_VBN to_TO fracture_NN
          prevention_NN [_NN 3_CD ]_NN ._. With_IN a_DT maximum_NN of_IN five_CD years_NNS of_IN
          follow-up_JJ ,_, a_DT total_NN of_IN 158_CD women_NNS were_VBD found_VBN to_TO have_VB breast_NN
          cancer_NN ,_, 131_CD of_IN which_WDT received_VBD the_DT diagnosis_NN more_JJR than_IN six_CD
          months_NNS after_IN enrollment_NN ,_, and_CC 102_CD of_IN which_WDT were_VBD invasive_JJ
          cancers_NNS ._. Treatment_NNP (_( alendronate_NN for_IN osteoporosis_NNS )_) in_IN the_DT
          randomized_JJ trial_NN did_VBD not_RB alter_VB breast_NN cancer_NN risk_NN ._. Age_NNP
          adjusted_VBD risk_NN increased_VBD with_IN increasing_VBG quartiles_NNS of_IN BMD_NNP ,_,
          though_IN marginal_JJ statistical_JJ significance_NN was_VBD achieved_VBN for_IN
          invasive_JJ cancer_NN only_RB in_IN the_DT highest_JJS versus_CC lowest_JJS BMD_NNP
          quartiles_NNS (_( OR_NNP =_SYM 1_CD ._. 8_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 0_CD -_: 3_CD ._. 2_LS )_) ._. Unlike_IN
          Framingham_NNP ,_, family_NN history_NN of_IN breast_NN cancer_NN did_VBD not_RB alter_VB
          the_DT results_NNS related_VBN to_TO BMD_NNP ._. Calcium_NNP and_CC vitamin_NN D_NNP
          ingestion_NN were_VBD found_VBN to_TO be_VB associated_VBN with_IN diminished_VBN
          breast_NN cancer_NN risk_NN ._. This_DT might_MD imply_VB that_IN the_DT estrogen_NN
          effect_NN on_IN breast_NN cancer_NN risk_NN ,_, as_IN manifested_JJ in_IN BMD_NNP ,_, could_MD
          have_VB been_VBN diminished_VBN by_IN increasing_VBG exposure_NN to_TO calcium_NN
          and_CC vitamin_NN D_NNP ._.
          An_DT indirect_JJ method_NN has_VBZ been_VBN employed_VBN to_TO assess_VB the_DT
          relationship_NN of_IN estrogen_NN exposure_NN to_TO breast_NN cancer_NN risk_NN
          through_IN bone_NN density_NN assessment_NN :_: the_DT association_NN of_IN
          osteoporotic_JJ fracture_NN to_TO the_DT prior_RB or_CC subsequent_JJ
          diagnosis_NN of_IN breast_NN and_CC uterine_NN cancer_NN (_( Table_NNP 7_CD )_) ._. One_CD
          recent_JJ large_JJ case_NN /_NN control_NN study_NN presents_VBZ compelling_JJ
          evidence_NN for_IN diminished_VBN risk_NN of_IN previous_JJ recent_JJ fracture_NN
          in_IN women_NNS with_IN both_DT breast_NN and_CC uterine_NN cancer_NN [_NN 19_CD ]_NN ._.
          Four_CD earlier_JJR reports_NNS of_IN fracture_NN and_CC breast_NN cancer_NN were_VBD
          evenly_RB divided_VBN in_IN their_PRP$ results_NNS ,_, though_IN the_DT negative_JJ
          studies_NNS included_VBD fracture_NN after_IN the_DT diagnosis_NN of_IN cancer_NN [_NN
          20_CD 21_CD 23_CD 24_CD ]_NN ._. Uterine_NNP cancer_NN has_VBZ also_RB been_VBN assessed_VBN in_IN
          all_DT but_CC one_CD of_IN these_DT reports_NNS [_NN 20_CD 22_CD 23_CD ]_NN and_CC found_VBD to_TO be_VB
          positively_RB associated_VBN with_IN fracture_NN in_IN two_CD ._.
        
        
          Colorectal_NNP cancer_NN
          The_DT results_NNS of_IN these_DT analyses_NNS show_VBP a_DT protective_JJ trend_NN
          of_IN BMD_NNP for_IN colorectal_NN cancer_NN that_WDT is_VBZ statistically_RB
          significant_JJ (_( Table_NNP 5_LS )_) ._. Estrogen_NNP is_VBZ thought_VBN to_TO diminish_VB
          risk_NN for_IN colorectal_NN cancer_NN ,_, though_IN there_EX has_VBZ been_VBN
          variation_NN in_IN findings_NNS concerning_VBG which_WDT subsite_NN within_IN the_DT
          colorectum_NN is_VBZ protected_VBN by_IN estrogen_NN exposure_NN ._. Other_JJ
          factors_NNS related_VBN to_TO BMD_NNP are_VBP also_RB thought_VBN to_TO effect_VB
          colorectal_NN cancer_NN risk_NN ,_, positively_RB (_( age_NN ,_, body_NN mass_NN index_NN ,_,
          smoking_NN )_) or_CC negatively_RB (_( calcium_NN ,_, estrogen_NN ,_, physical_JJ
          activity_NN )_) [_NN 9_CD 10_CD ]_NN ._. Of_IN these_DT ,_, the_DT most_RBS widely_RB
          investigated_VBN has_VBZ been_VBN calcium_NN ._. Twenty-four_CD analytic_JJ
          studies_NNS of_IN calcium_NN in_IN cohort_NN and_CC case_NN /_NN control_NN designs_NNS
          have_VBP been_VBN reported_VBN ._. Only_RB ten_CD of_IN these_DT have_VBP shown_VBN a_DT
          significant_JJ decrease_NN in_IN colon_NN cancer_NN risk_NN associated_VBN with_IN
          calcium_NN intake_NN ._. In_IN addition_NN ,_, there_EX have_VBP been_VBN 8_CD studies_NNS of_IN
          vitamin_NN D_NNP intake_NN ,_, only_RB 3_CD of_IN which_WDT have_VBP shown_VBN decreased_VBN
          colorectal_NN cancer_NN risk_NN related_VBN to_TO increased_VB vitamin_NN D_NNP [_NN
          25_CD ]_NN ._.
          The_DT reason_NN for_IN these_DT inconsistent_JJ results_NNS relating_VBG to_TO
          calcium_NN may_MD be_VB that_DT calcium_NN nutriture_NN is_VBZ difficult_JJ to_TO
          measure_VB ._. Bioavailability_NNP of_IN calcium_NN is_VBZ related_VBN to_TO the_DT
          intake_NN of_IN other_JJ nutrients_NNS ,_, which_WDT include_VBP dietary_JJ fiber_NN
          (_( phytate_NN )_) ,_, phosphate_NN ,_, alcohol_NN ,_, and_CC tea_NN (_( tannins_NNS )_) ._. Each_DT
          can_MD alter_VB colorectal_NN cancer_NN risk_NN ._. Therefore_RB ,_, serum_NN
          calcium_NN levels_NNS and_CC dietary_JJ intake_NN do_VBP not_RB necessarily_RB
          reflect_VB endogenous_JJ content_NN ._. As_IN with_IN iron_NN ,_, endogenous_JJ
          calcium_NN stores_NNS may_MD be_VB the_DT more_RBR significant_JJ effector_NN of_IN
          risk_NN than_IN dietary_JJ calcium_NN intake_NN [_NN 26_CD ]_NN ._. In_IN the_DT case_NN of_IN
          calcium_NN ,_, the_DT measure_NN of_IN endogenous_JJ stores_NNS is_VBZ BMD_NNP ._.
          The_DT investigation_NN of_IN BMD_NNP and_CC colorectal_NN cancer_NN risk_NN ,_,
          therefore_RB ,_, provides_VBZ a_DT new_JJ perspective_NN in_IN the_DT analysis_NN of_IN
          calcium_NN and_CC colorectal_NN cancer_NN risk_NN ,_, and_CC in_IN addition_NN
          provides_VBZ information_NN on_IN two_CD other_JJ factors_NNS for_IN colorectal_NN
          cancer_NN that_WDT are_VBP thought_VBN to_TO diminish_VB risk_NN :_: physical_JJ
          activity_NN and_CC estrogen_NN [_NN 10_CD ]_NN ._. This_DT is_VBZ the_DT first_JJ such_JJ
          report_NN analyzing_VBG this_DT association_NN ._.
        
        
          Prostatic_NNP cancer_NN
          Reported_NNP herein_NN is_VBZ the_DT first_JJ study_NN to_TO obtain_VB BMD_NNP
          measurement_NN prior_RB to_TO the_DT diagnosis_NN of_IN prostate_NN cancer_NN ,_,
          and_CC no_DT association_NN was_VBD found_VBN (_( Table_NNP 6_CD )_) ._. Calcium_NNP ingestion_NN
          has_VBZ also_RB been_VBN associated_VBN with_IN increased_VBN risk_NN of_IN prostate_NN
          cancer_NN [_NN 10_CD 11_CD ]_NN ._. The_DT only_JJ study_NN to_TO look_VB at_IN BMD_NNP and_CC
          prostate_NN cancer_NN risk_NN was_VBD a_DT case_NN /_NN control_NN design_NN ._. It_PRP showed_VBD
          no_DT association_NN ,_, although_IN cases_NNS already_RB had_VBD prostate_NN
          cancer_NN when_WRB BMD_NNP was_VBD measured_VBN and_CC controls_NNS were_VBD patients_NNS
          with_IN other_JJ urologic_JJ diseases_NNS or_CC presenting_VBG for_IN prostate_NN
          cancer_NN screening_NN [_NN 27_CD ]_NN ._.
        
        
          BMD_NNP and_CC estrogen_NN
          BMD_NNP is_VBZ affected_VBN by_IN many_JJ factors_NNS other_JJ than_IN estrogen_NN ,_,
          including_VBG principally_RB age_NN ,_, calcium_NN ,_, body_NN mass_NN index_NN ,_,
          cigarette_NN smoking_NN ,_, physical_JJ activity_NN ,_, and_CC prior_RB bone_NN
          injury_NN ._. As_IN such_JJ it_PRP is_VBZ a_DT non-specific_JJ indicator_NN of_IN risk_NN ._.
          BMD_NNP was_VBD also_RB measured_VBN in_IN NHANES_NNP I_PRP at_IN a_DT time_NN when_WRB
          post-menopausal_JJ use_NN of_IN estrogen_NN was_VBD rare_JJ ._. Its_PRP$ increasing_VBG
          use_NN in_IN recent_JJ decades_NNS may_MD have_VB altered_VBN the_DT subsequent_JJ
          risk_NN of_IN cancer_NN in_IN these_DT women_NNS ._. Nevertheless_RB ,_, the_DT results_NNS
          seen_VBN in_IN opposite_JJ directions_NNS in_IN uterus_NN and_CC colorectum_NN
          suggest_VBP that_DT estrogen_NN exposure_NN at_IN least_JJS up_IN to_TO the_DT point_NN
          at_IN which_WDT BMD_NNP was_VBD measured_VBN was_VBD a_DT significant_JJ mediator_NN of_IN
          risk_NN for_IN cancer_NN in_IN NHANES_NNP I_PRP ._. The_DT weakly_RB positive_JJ results_NNS
          for_IN breast_NN cancer_NN in_IN combination_NN with_IN previously_RB
          published_VBN reports_NNS suggest_VBP that_IN ,_, unlike_IN the_DT other_JJ
          endpoints_NNS reported_VBD herein_NN ,_, BMD_NNP as_IN a_DT predictor_NN of_IN breast_NN
          cancer_NN risk_NN is_VBZ only_RB of_IN use_NN when_WRB measured_VBN after_IN
          menopause_NN ._.
        
      
      
        Conclusions_NNP
        In_IN summary_NN ,_, this_DT NHANES_NNP I_PRP cohort_NN follow-up_JJ is_VBZ the_DT first_JJ
        report_NN of_IN analyses_NNS of_IN BMD_NNP and_CC subsequent_JJ risk_NN for_IN cancer_NN of_IN
        the_DT colorectum_NN and_CC uterus_NN ,_, the_DT fourth_JJ for_IN breast_NN cancer_NN
        risk_NN and_CC the_DT second_NN for_IN prostate_NN cancer_NN ._. A_DT strong_JJ positive_JJ
        association_NN was_VBD seen_VBN between_IN BMD_NNP and_CC corpus_NN uteri_NN cancer_NN ,_,
        and_CC a_DT significant_JJ trend_NN towards_IN decreasing_VBG colorectal_NN
        cancer_NN risk_NN with_IN increasing_VBG BMD_NNP ._. There_EX is_VBZ an_DT insignificant_JJ
        decline_NN in_IN risk_NN for_IN prostate_NN cancer_NN with_IN increasing_VBG BMD_NNP ,_, a_DT
        direction_NN opposite_NN of_IN our_PRP$ initial_JJ hypothesis_NNS ._. A_DT weak_JJ
        relationship_NN could_MD be_VB detected_VBN between_IN breast_NN cancer_NN and_CC
        BMD_NNP only_RB when_WRB BMD_NNP was_VBD measured_VBN after_IN menopause_NN ._. Significant_JJ
        inverse_NN associations_NNS were_VBD found_VBN between_IN BMD_NNP ,_, osteoporosis_NNS
        and_CC hip_NN fracture_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Author_NN 's_POS Contributions_NNP
        R_NN ._. Nelson_NNP ;_: Conceived_NNP the_DT study_NN ,_, wrote_VBD the_DT paper_NN ,_,
        reviewed_VBD relevant_JJ literature_NN ._. V_NNP ._. Persky_NNP ;_: Provided_VBN overall_JJ
        epidemiologic_JJ expertise_NN and_CC guidance_NN ._. M_NNP ._. Turyk_NNP &_CC J_NNP ._.
        Kim_NNP ;_: Accessed_NNP NHANES_NNP tapes_NNS ,_, downloaded_JJ data_NNS and_CC performed_VBN
        statistical_JJ analyses_NNS and_CC wrote_VBD most_JJS of_IN the_DT methods_NNS
        sections_NNS ._. All_DT authors_NNS reviewed_VBD the_DT manuscript_NN and_CC
        contributed_VBD to_TO it_PRP ._.
      
    
  
